Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...

In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...

Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of its ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Akero Therapeutics reports positive mid-stage data for efruxifermin - its candidate treatment for cirrhosis. Akero stock rallied over 100%.

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...